No Data
Zhejiang hisoar pharmaceutical (002099.SZ): The company's dye sector sales in the first to third quarters have slightly increased compared to last year.
Gelonghui, November 27 - Zhejiang Hisoar Pharmaceutical (002099.SZ) recently stated in investor relations activities that there is currently no sign of a recovery in the cyclicality of the dye industry. The company's sales in the dye sector for the first to third quarters have slightly increased compared to last year. The company is actively laying out emerging fields such as digital inkjet printing, high-performance dye pigments, and liquid crystals to promote the quality upgrade of the industry chain and enhance the company's competitiveness in the industry.
Zhejiang hisoar pharmaceutical (002099.SZ): The peptide platform project has successfully integrated into the industry chain supporting original research pharmaceutical companies and has achieved partial product commercialization supply.
GeLongHui, November 27th | zhejiang hisoar pharmaceutical (002099.SZ) stated in recent investor relations activities that the company's polypeptide platform project has successfully entered the original drug enterprise supporting industry chain and achieved partial commercial supply of products. The company will continue to expand new project verification cooperation, promote domestic and foreign collaborations with other pharmaceutical companies, and increase product market share.
Zhejiang Hisoar Pharmaceutical (002099.SZ): The client's non-sterile active pharmaceutical ingredient project for Peinan Original Research has completed the validation batch delivery.
On November 27, Gelonghui reported that Zhejiang Hisoar Pharmaceutical (002099.SZ) stated during a recent investor relations event that the company maintains a dual-driven development in the CMO/CDMO business, leveraging both production advantages and business development expansion. There is a good growth momentum for existing products with strategic partner customers, and the pace of onboarding new projects is accelerating. The non-sterile active pharmaceutical ingredient project for the original research customer has completed the validation batch delivery and is cooperating with the customer on global market certification; additionally, other anti-infection projects are in the validation batch stage.
Haixiang Pharmaceutical: Report for the third quarter of 2024
Haixiang Pharmaceutical: 2024 Semi-Annual Report Summary
Haixiang Pharmaceutical: 2024 Semi-Annual Report
No Data
No Data